Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T Blumenthal

Showing results (201-210 of 224) with videos related to

Pageof 23
Sort By:
Frontiers in Oncology|July 15, 2022
A Prospective, Cohort Study of SITOIGANAP to Treat Glioblastoma When Given in Combination With Granulocyte-Macrophage Colony-Stimulating Factor/Cyclophosphamide/Bevacizumab/Nivolumab or Granulocyte-Macrophage Colony-Stimulating Factor/Cyclophosphamide/Bevacizumab/Pembrolizumab in Patients Who Failed Prior Treatment With Surgical Resection, Radiation, and TemozolomideDaniela A Bota, Thomas H Taylor, Naomi Lomeli, et al.
Cancer|April 29, 2020
Optimal timing of chemoradiotherapy after surgical resection of glioblastoma: Stratification by validated prognostic classificationRobert H Press, Sarah L Shafer, Renjian Jiang, et al.
Proceedings of the National Academy of Sciences of the United States of America|August 7, 2023
Collaborative privacy-preserving analysis of oncological data using multiparty homomorphic encryptionRavit Geva, Alexander Gusev, Yuriy Polyakov, et al.
Neuro-Oncology|December 18, 2019
Safety and efficacy of VB-111, an anticancer gene therapy, in patients with recurrent glioblastoma: results of a phase I/II studyAndrew J Brenner, Katherine B Peters, James Vredenburgh, et al.
Neuro-Oncology|February 21, 2018
Short delay in initiation of radiotherapy for patients with glioblastoma-effect of concurrent chemotherapy: a secondary analysis from the NRG Oncology/Radiation Therapy Oncology Group databaseDeborah T Blumenthal, Minhee Won, Minesh P Mehta, et al.
Neuro-Oncology|April 29, 2017
An independently validated nomogram for individualized estimation of survival among patients with newly diagnosed glioblastoma: NRG Oncology RTOG 0525 and 0825Haley Gittleman, Daniel Lim, Michael W Kattan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 9, 2013
Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trialMark R Gilbert, Meihua Wang, Kenneth D Aldape, et al.
Neuro-Oncology|December 3, 2014
Delayed contrast extravasation MRI: a new paradigm in neuro-oncologyLeor Zach, David Guez, David Last, et al.
Journal for Immunotherapy of Cancer|June 6, 2025
In-depth characterization of vaccine-induced neoantigen-specific T cells in patients with IDH1-mutant glioma undergoing personalized peptide vaccinationHenning Zelba, Borong Shao, Armin Rabsteyn, et al.
JAMA Oncology|January 19, 2017
Molecular-Based Recursive Partitioning Analysis Model for Glioblastoma in the Temozolomide Era: A Correlative Analysis Based on NRG Oncology RTOG 0525Erica Hlavin Bell, Stephanie L Pugh, Joseph P McElroy, et al.
Pageof 23

Showing results (201-210 of 224) with videos related to

Sort By:
Pageof 23
Frontiers in Oncology|July 15, 2022
A Prospective, Cohort Study of SITOIGANAP to Treat Glioblastoma When Given in Combination With Granulocyte-Macrophage Colony-Stimulating Factor/Cyclophosphamide/Bevacizumab/Nivolumab or Granulocyte-Macrophage Colony-Stimulating Factor/Cyclophosphamide/Bevacizumab/Pembrolizumab in Patients Who Failed Prior Treatment With Surgical Resection, Radiation, and TemozolomideDaniela A Bota, Thomas H Taylor, Naomi Lomeli, et al.
Cancer|April 29, 2020
Optimal timing of chemoradiotherapy after surgical resection of glioblastoma: Stratification by validated prognostic classificationRobert H Press, Sarah L Shafer, Renjian Jiang, et al.
Proceedings of the National Academy of Sciences of the United States of America|August 7, 2023
Collaborative privacy-preserving analysis of oncological data using multiparty homomorphic encryptionRavit Geva, Alexander Gusev, Yuriy Polyakov, et al.
Neuro-Oncology|December 18, 2019
Safety and efficacy of VB-111, an anticancer gene therapy, in patients with recurrent glioblastoma: results of a phase I/II studyAndrew J Brenner, Katherine B Peters, James Vredenburgh, et al.
Neuro-Oncology|February 21, 2018
Short delay in initiation of radiotherapy for patients with glioblastoma-effect of concurrent chemotherapy: a secondary analysis from the NRG Oncology/Radiation Therapy Oncology Group databaseDeborah T Blumenthal, Minhee Won, Minesh P Mehta, et al.
Neuro-Oncology|April 29, 2017
An independently validated nomogram for individualized estimation of survival among patients with newly diagnosed glioblastoma: NRG Oncology RTOG 0525 and 0825Haley Gittleman, Daniel Lim, Michael W Kattan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 9, 2013
Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trialMark R Gilbert, Meihua Wang, Kenneth D Aldape, et al.
Neuro-Oncology|December 3, 2014
Delayed contrast extravasation MRI: a new paradigm in neuro-oncologyLeor Zach, David Guez, David Last, et al.
Journal for Immunotherapy of Cancer|June 6, 2025
In-depth characterization of vaccine-induced neoantigen-specific T cells in patients with IDH1-mutant glioma undergoing personalized peptide vaccinationHenning Zelba, Borong Shao, Armin Rabsteyn, et al.
JAMA Oncology|January 19, 2017
Molecular-Based Recursive Partitioning Analysis Model for Glioblastoma in the Temozolomide Era: A Correlative Analysis Based on NRG Oncology RTOG 0525Erica Hlavin Bell, Stephanie L Pugh, Joseph P McElroy, et al.
Pageof 23